Biocon Biologics has entered a five-year partnership with Sandoz Australia, granting exclusive rights for the marketing and distribution of cancer biosimilars, Ogivri and Fulphila, in Australia. Ogivri is a biosimilar of Trastuzumab (Herceptin), and Fulphila is a biosimilar of Pegfilgrastim. The collaboration, following a recent alliance in Japan, aims to ensure Australian patients’ continued access to high-quality and affordable biosimilar oncology medications. Sandoz will distribute Biocon Biologics’ brands, providing a strategic move in the global growth strategy, and the partnership is effective from January 1, 2024, with commercialization beginning on February 1, 2024.
Biocon Biologics Partners with Sandoz Australia for Cancer Biosimilars Distribution
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2024/02/09171955/1628593401-9675-ezgif.com-avif-to-jpg-converter.jpg)